SCHEMBL5689668

SCHEMBL5689668

CC1CCN(C(=S)Nc2ccc(OC(=O)N(C)c3ccccc3)nc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.47
ALDH1A1 P00352 5/20 0.44
NPY2R P49146 3/20 0.43
GAA P10253 2/20 0.42
KMT2A Q03164 4/20 0.42
KDM4E B2RXH2 3/20 0.42
TDP1 Q9NUW8 1/20 0.42
NPC1 O15118 3/20 0.41
LMNA P02545 2/20 0.41
RAB9A P51151 2/20 0.41
HPGD P15428 1/20 0.41
MEN1 O00255 2/20 0.41
LIPE Q05469 1/20 0.41
NAMPT P43490 1/20 0.41
ADRB2 P07550 1/20 0.41
ADRB3 P13945 1/20 0.41
TSPO P30536 1/20 0.41
TMEM97 Q5BJF2 1/20 0.41
GPR65 Q8IYL9 1/20 0.41
RECQL P46063 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5687800 0.89 ALDH1A1 (0.47) SMN1; SMN2ALDH1A1GAAKMT2ATDP1
SCHEMBL5688070 0.86 KMT2A (0.41) ALDH1A1NPY2RKMT2ANPC1LMNA
SCHEMBL5687627 0.81 NPC1 (0.51) SMN1; SMN2ALDH1A1GAAKMT2ANPC1
SCHEMBL5687639 0.81 CXCR1 (0.49) SMN1; SMN2ALDH1A1KMT2AKDM4ENPC1
SCHEMBL5687502 0.81 CXCR1 (0.46) SMN1; SMN2ALDH1A1KMT2ANPC1LMNA
SCHEMBL5687145 0.78 PKM (0.49) SMN1; SMN2ALDH1A1GAAKMT2ATDP1
SCHEMBL5646367 0.77 ALDH1A1 (0.49) SMN1; SMN2ALDH1A1KMT2AKDM4ENPC1
SCHEMBL5689973 0.76 MCHR1 (0.45) SMN1; SMN2ALDH1A1GAAKMT2AKDM4E
SCHEMBL5687198 0.76 NPC1 (0.45) SMN1; SMN2ALDH1A1KMT2AKDM4ENPC1
SCHEMBL5647960 0.76 CXCR1 (0.56) SMN1; SMN2GAAKMT2AKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160865-A1 Pyridinyl carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636205-A1 PYRIDINYL CARBAMATES AS HORMONE-SENSITIVE LIPASE INHIBITORS NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111031-A1 PYRIDINYL CARBAMATES AS HORMONE-SENSITIVE LIPASE INHIBITORS NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
US-20060160865-A1 Pyridinyl carbamates NOVO NORDISK A/S (DK) 2006-07-20 US disclosed
EP-1636205-A1 PYRIDINYL CARBAMATES AS HORMONE-SENSITIVE LIPASE INHIBITORS NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111031-A1 PYRIDINYL CARBAMATES AS HORMONE-SENSITIVE LIPASE INHIBITORS NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160865-A1 Pyridinyl carbamates LIPE, PNLIP, LPL SMN1; SMN2 2486/4885ALDH1A1 2231/4885NPY2R 1319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.